Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5

Conditions

Lung Neoplasms 77Leukemia, Myeloid, Acute 68Prostatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 56Neoplasm Metastasis 55Breast Neoplasms 50Multiple Myeloma 42Colorectal Neoplasms 39Pancreatic Neoplasms 33Carcinoma, Renal Cell 33Myelodysplastic Syndromes 31Melanoma 30Leukemia, Lymphocytic, Chronic, B-Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 25Glioblastoma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Urinary Bladder Neoplasms 22Lymphoma 22Burkitt Lymphoma 21Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Hepatocellular 19Glioma 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Lymphoma, Follicular 15Leukemia, Biphenotypic, Acute 15

Interventions

Doxorubicin 6Specimen Handling 5Radiotherapy 3Radiation 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3pembrolizumab 2liposomal doxorubicin 2eribulin 2durvalumab 2Ifosfamide 2Dacarbazine 2tremelimumab 1toripalimab 1talimogene laherparepvec 1rucaparib 1ribociclib 1regorafenib 1peposertib 1pazopanib 1olaratumab 1olaparib 1lenvatinib 1futibatinib 1dinutuximab 1cemiplimab 1cediranib 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Leiomyosarcoma × Specimen Handling × 1 year × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06571734 2026-01-09

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Northwestern University

Phase 2 Recruiting
29 enrolled
Sarcoma

Leiomyosarcoma

NCT06528769 2025-09-30

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
16 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡